CTXR · Citius Pharmaceuticals, Inc.

The 2026 annual meeting resulted in full board renewal with all seven nominees elected, indicating no contested director elections or shareholder opposition to incumbent leadership. The overwhelming ratification of Wolf & Company, P.C. as auditor—supported by ~85% of votes cast—confirms continued confidence in financial oversight and audit continuity. Notably, the withheld votes for each director nominee equal 6,660,992 across all candidates, suggesting a standardized proxy voting instruction (e.g., withhold authority for discretionary votes) rather than candidate-specific dissent. The absence of broker non-votes for the auditor proposal reflects that all shares eligible to vote were voted, consistent with routine ratification matters where brokers may vote without instructions. While governance stability is reinforced, the filing discloses no changes to board composition, committee assignments, or executive compensation plans, limiting near-term strategic implications for investors.